These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 3764307)
21. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894 [TBL] [Abstract][Full Text] [Related]
22. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon. Creager MA; Pariser KM; Winston EM; Rasmussen HM; Miller KB; Coffman JD Am Heart J; 1984 Aug; 108(2):370-3. PubMed ID: 6380254 [TBL] [Abstract][Full Text] [Related]
23. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Thompson AE; Shea B; Welch V; Fenlon D; Pope JE Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437 [TBL] [Abstract][Full Text] [Related]
24. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study. White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931 [TBL] [Abstract][Full Text] [Related]
25. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon]. Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886 [TBL] [Abstract][Full Text] [Related]
26. Rational use of calcium-channel antagonists in Raynaud's phenomenon. Sturgill MG; Seibold JR Curr Opin Rheumatol; 1998 Nov; 10(6):584-8. PubMed ID: 9812220 [TBL] [Abstract][Full Text] [Related]
27. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Corbin DO; Wood DA; Macintyre CC; Housley E Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704 [TBL] [Abstract][Full Text] [Related]
28. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. Wollersheim H; Thien T; van 't Laar A J Clin Pharmacol; 1987 Nov; 27(11):907-13. PubMed ID: 3429697 [TBL] [Abstract][Full Text] [Related]
29. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Kahan A; Amor B; Menkes CJ Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061 [TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy of Raynaud's phenomenon. Belch JJ; Ho M Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818 [TBL] [Abstract][Full Text] [Related]
32. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Ettinger WH; Wise RA; Schaffhauser D; Wigley FM Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986 [TBL] [Abstract][Full Text] [Related]
33. The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon. Francis JL; Roath OS; Challenor VF; Waller DG Br J Clin Pharmacol; 1988 Jun; 25(6):751-4. PubMed ID: 3203045 [TBL] [Abstract][Full Text] [Related]
34. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease. Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066 [TBL] [Abstract][Full Text] [Related]